Montelukast in asthma: A review of its efficacy and place in therapy

Therapeutic Advances in Chronic Disease

Volumn 2, Issue 1, 2011, Pages 47-58

  Paggiaro, Pierluigi ^a   Bacci, Elena ^b  

^a CISANELLO HOSPITAL   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

asthma; montelukast; phenotype; remodelling

Indexed keywords

ACETYLSALICYLIC ACID; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; DESLORATADINE; FLUTICASONE; LEUKOTRIENE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PLACEBO; SALMETEROL;

ADD ON THERAPY; ALLERGIC RHINITIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; CHURG STRAUSS SYNDROME; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXERCISE; HUMAN; LOW DRUG DOSE; OBESITY; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK FACTOR; SMOKING; SUICIDE; SYSTEMIC VASCULITIS; WHEEZING;

EID: 79960066863     PISSN: 20406223     EISSN: 20406231     Source Type: Journal    
DOI: 10.1177/2040622310383343     Document Type: Review

References (65)

1. Altraja S. Kadai M. Rekker E. Altraja A. (2008) Synthesis of tenascin and laminin beta 2 chain in human bronchial epithelial cells is enhanced by cysteinyl leukotrienes via CysLT 1 receptor. Respir Res 9: 44–53.
2. Asakura T. Ishii Y. Chibana K. Fukuda T. (2004) Leukotriene D 4 stimulates collagen production from myofibroblasts transformed by TGF-beta. J Allergy Clin Immunol 114: 310–315.
3. Bacci E. Cianchetti S. Bartoli M. Dente F.L. Di Franco A. Vagaggini B. et al (2006) Low sputum eosinophils predict the lack of response to beclomethasone in symptomatic asthmatic patients. Chest 129: 565–572.
4. Bacci, E., Di Franco, A., Dente, F.L., Bartoli, M.L., Cianchetti, S., Vagaggini, B. et al. (2010) Short-term effects of oral zafirlukast on sputum eosinophilia in mild asthmatics: Comparison with inhaled corticosteroids (submitted).
5. Barnes N. Thomas M. Price D. Tate H. (2005) The national montelukast survey. J Allergy Clin Immunol 115: 47–54.
6. Barnes N. Wei L.X. Reiss T.F. Leff J.A. Shingo S. Yu C. et al (2001) Analysis of montelukast in mild persistent asthmatic patients with near-normal lung function. Respir Med 95: 379–386.
7. Bartoli M.L. Dente F.L. Bancalari L. Bacci E. Cianchetti S. Di Franco A. et al (2010) Beclomethasone propionate blunts allergen-induced early increase in urinary LTE4. Eur J Clin Invest 40: 566–569.
8. Bisgaard H. Skoner D. Boza M.L. Tozzi C.A. Newcomb K. Reiss T.F. et al (2009) Safety and tolerability of montelukast in placebo-controlled pediatric studies and their open-label extensions. Pediatr Pulmonol 44: 568–579.
9. Bisgaard H. Study Group on Montelukast and Respiratory Syncytial Virus (2003) A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis. Am J Respir Crit Care Med 167: 379–383.
10. Bjermer L. Bisgaard H. Bousquet J. Fabbri L.M. Greening A.P. Haahtela T. et al (2003) Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: One year, double blind, randomised, comparative trial. BMJ 327: 891–896.
11. Borderias L. Mincewicz G. Paggiaro P.L. Guilera M. Sazonov Kocevar V. Taylor S.D. et al (2007) Asthma control in patients with asthma and allergic rhinitis receiving add-on montelukast therapy for 12 months: A retrospective observational study. Curr Med Res Opin 23: 721–730.
12. Bousquet J. Gaugris S. Kocevar V.S. Zhang Q. Yin D.D. Polos P.G. et al (2005) Increased risk of asthma attacks and emergency visits among asthma patients with allergic rhinitis: A subgroup analysis of the investigation of montelukast as a partner agent for complementary therapy. Clin Exp Allergy 35: 723–727.
13. Busse W. Raphael G. Galant S. Kalberg C. Goode-Sellers S. Srebro S. et al (2001) Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: A randomized clinical trial. J Allergy Clin Immunol 107: 461–468.
14. Currie G.P. Lipworth B.J. (2002) Bronchoprotective effects of leukotriene receptor antagonists in asthma. A meta-analysis. Chest 122: 146–150.
15. Dahlén S.E. Malmström K. Nizankowska E. Dahlén B. Kuna P. Kowalski M. et al (2002) Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: A randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 165: 9–14.
16. Davis B.E. Illamperuma C. Gauvreau G.M. Watson R.M. O'Byrne P.M. Deschesnes F. et al (2009) Single-dose desloratadine and montelukast and allergen-induced late airway responses. Eur Respir J 33: 1302–1308.
17. Deykin A. Wechsler M.E. Boushey H.A. Chinchilli V.M. Kunselman S.J. Craig T.J. et al (2007) Combination therapy with a long-acting beta-agonist and a leukotriene antagonist in moderate asthma. Am J Respir Crit Care Med 175: 228–234.
18. Doull I.J. (2004) The effect of asthma and its treatment on growth. Arch Dis Child 89: 60–63.
19. Ducharme F.M. (2002) Anti-leukotrienes as add-on therapy to inhaled glucocorticoids in patients with asthma: Systematic review of current evidence. BMJ 324: 1545–1552.
20. Dworski R. Fitzgerald G.A. Oates J.A. Sheller J.R. (1994) Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am J Respir Crit Care Med 149: 953–959.
21. Fish J.E. Israel E. Murray J.J. Emmett A. Boone R. Yancey S.W. et al (2001) Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. Chest 120: 423–430.
22. Fitzgerald D.A. Mellis C.M. (2006) Leukotriene receptor antagonists in virus-induced wheezing: Evidence to date. Treat Respir Med 5: 407–417.
23. Gaber F. Daham K. Higashi A. Higashi N. Gülich A. Delin I. et al (2008) Increased levels of cysteinyl-leukotrienes in saliva, induced sputum, urine and blood from patients with aspirin-intolerant asthma. Thorax 63: 1076–1082.
24. Global Initiative for Asthma (2009) www.ginasthma.org.
25. Hamid Q. Tulic M.K. Liu M.C. Moqbel R. (2003) Inflammatory cells in asthma: Mechanisms and implications for therapy. J Allergy Clin Immunol 111(Suppl 1): S5–S17.
26. Han J. Jia Y. Takeda K. Shiraishi Y. Okamoto M. Dakhama A. et al (2010) Montelukast during primary infection prevents airway hyperresponsiveness and inflammation following re-infection with respiratory syncytial virus. Am J Respir Crit Care Med[Epub ahead of print].
27. Hauser T. Mahr A. Metzler C. Coste J. Sommerstein R. Gross W.L. et al (2008) The leukotriene receptor antagonist montelukast and the risk of Churg–Strauss syndrome: A case-crossover study. Thorax 63: 677–682.
28. Holgate S.T. Peters-Golden M. Panettieri R.A. Henderson W.R. (2003) Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodelling. J Allergy Clin Immunol 111(Suppl 1): S18–S34.
29. Jayaram I. Pizzichini E. Lemière C. Man S.F. Cartier A. Hargreave F.E. et al (2005) Steroid naive eosinophilic asthma: Anti-inflammatory effects of fluticasone and montelukast. Thorax 60: 100–105.
30. Joos S. Miksch A. Szemcsenyi J. Wieseler B. Grouven U. Kaiser T. et al (2008) Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: A systematic review. Thorax 63: 453–462.
31. Klotsman M. York T.P. Pillai S.G. Vargas-Irwin C. Sharma S.S. van den Oord E.J. et al (2007) Pharmacogenetics of the 5-lipoxygenase biosynthetic pathway and variable clinical response to montelukast. Pharmacogenet Genomics 17: 189–196.
32. Korn D. van den Brande P. Potvin E. Dramaix M. Herbots E. Peché R. (2009) Efficacy of add-on montelukast in patients with non-controlled asthma: A Belgian open-label study. Curr Med Res Opin 25: 489–497.
33. Laitinen A. Lindqvist A. Halme M. Altraja A. Laitinen L.A. (2005) Leukotriene E (4)-induced persistent eosinophilia and airway obstruction are reversed by zafirlukast in patients with asthma. J Allergy Clin Immunol 115: 259–265.
34. Laviolette M. Malmstrom K. Lu S. Chervinsky P. Pujet J.C. Peszek I. et al (1999) Montelukast added to inhaled beclomethasone in treatment of asthma. Am J Respir Crit Care Med 160: 1862–1868.
35. Lazarus S.C. Chinchilli V.M. Rollings N.J. Boushey H.A. Cherniack R. Craig T.J. et al (2007) Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med 175: 783–790.
36. Leff J.A. Busse W.W. Pearlman D. Bronsky E.A. Kemp J. Hendeles L. et al (1998) Montelukast, a leukotriene receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. New Engl J Med 339: 147–152.
37. Leigh R. Vethanayagam D. Yoshida M. Watson R.M. Rerecich T. Inman M.D. et al (2002) Effect of montelukast and budesonide on airway responses and airway inflammation in asthma. Am J Respir Crit Care Med 166: 1212–1217.
38. Lemanske R.F. Jr Mauger D.T. Sorkness C.A. Jackson D.J. Boehmer S.J. Martinez F.D. et al (2010) Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med 362: 975–985.
39. Löfdahl C.G. Reiss T.F. Leff J.A. Israel E. Noonan M.J. Finn A.F. et al (1999) Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ 319: 87–90.
40. Lugogo N.L. Kraft M. Dixon A.E. (2010) Does obesity produce a distinct asthma phenotype? J Appl Physiol 108: 729–734.
41. Maeba S. Ichiyama T. Ueno Y. Makata H. Matsubara T. Furukawa S. (2005) Effect of montelukast on nuclear factor kappaB activation and proinflammatory molecules. Ann Allergy Asthma Immunol 94: 670–674.
42. Malmstrom K. Rodriguez-Gomez G. Guerra J. Villaran C. Piñeiro A. Wei L.X. et al (1999) Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. Ann Intern Med 130: 487–495.
43. McIvor R.A. Kaplan A. Koch C. Sampalis J.S. (2009) Montelukast as an aternative to low-dose inhaled corticosteroids in to management of mild asthma (the SIMPLE trial): An open-label effectiveness trial. Can Respir J 16(Suppl A): 11A–21A.
44. Mechiche H. Naline E. Candenas L. Pinto F.M. Birembault P. Advenier C. et al (2003) Effects of cysteinyl leukotrienes in small human bronchus and antagonist activity of montelukast and its metabolites. Clin Exp Allergy 33: 887–894.
45. Nayak A. Langdon R.B. (2007) Montelukast in the treatment of allergic rhinitis: An evidence-based review. Drugs 67: 887–901.
46. O'Shaugnessy K.M. Wellings R. Gillies B. Fuller R.W. (1993) Differential effects of fluticasone proprionate on allergen-evoked bronchoconstriction and increased urinary LTE 4 excretion. Am Rev Respir Dis 147: 1472–1476.
47. Oommen A. Grigg J. (2003) Urinary leukotriene E 4 in preschool children with acute clinical viral wheeze. Eur Respir J 21: 149–154.
48. Peters-Golden M. Swern A. Bird S.S. Hustad C.M. Grant E. Edelman J.M. (2006) Influence of body mass index on the response to asthma controller agents. Eur Respir J 27: 495–503.
49. Philip G. Hurstad C.M. Malice P.M. Noonan G. Ezekowitz A. Reiss T.F. et al (2009 a) Analysis of behavior-related adverse experiences in clinical trials of montelukast. J Allergy Clin Immunol 124: 699–706.
50. Philip G. Hustad C. Noonan G. Malice M.P. Ezekowitz A. Reiss T.F. et al (2009 b) Reports of suicidality in clinical trials of montelukast. J Allergy Clin Immunol 124: 691–696.
51. Philip G. Nayak A.S. Berger W.E. Leynadier F. Vrijens F. Dass S.B. et al (2004) The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis. Curr Med Res Opin 20: 1549–1558.
52. Pizzichini E. Leff J.A. Reiss T.F. Hendeles L. Boulet L.P. Wei L.X. et al (1999) Montelukast reduces airway eosinophilic inflammation in asthma: A randomized, controlled trial. Eur Respir J 14: 12–18.
53. Price D.B. Swern A. Tozzi C.A. Philip G. Polos P. (2006) Effect of montelukast on lung function in asthma patients with allergic rhinitis: Analysis from the COMPACT trial. Allergy 61: 737–742.
54. Raissy H.H. Harkins M. Kelly F. Kelly H.W. (2008) Pretreatment with albuterol versus montelukast for exercise-induced bronchospasm in children. Pharmacotherapy 28: 287–294.
55. Ramsay C.F. Sullivan P. Gizycki M. Wang D. Swern A.S. Barnes N.C. et al (2009) Montelukast and bronchial inflammation in asthma: A randomised, double-blind placebo-controlled trial. Respir Med 103: 995–1003.
56. Reiss T.F. Chervinsky P. Dockhorn R.J. Shingo S. Seidenberg B. Edwards T.B. et al (1998) Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma. A multicenter, randomized, double-blnd trial. Arch Int Med (Chic) 158: 1213–1220.
57. Robinson D.S. Campbell D. Barnes P.J. (2001) Addition of leukotriene antagonists to therapy in chronic persistent asthma: A randomised double-blind placebo-controlled trial. Lancet 357: 2007–2011.
58. Sandrini A. Ferreira I.M. Gutierrez C. Jardim J.R. Zamel N. Chapman K.R. (2003) Effect of montelukast on exhaled nitric oxide and nonvolatile markers of inflammation in mild asthma. Chest 124: 1334–1340.
59. Szefler S.J. Phillips B.R. Martinez F.D. Chinchilli V.M. Lemanske R.F. Strunk R.C. et al (2005) Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 115: 233–242.
60. Tohda Y. Fujimura M. Taniguchi H. Takagi K. Igarashi T. Yasuhara H. et al (2002) Leukotriene receptor antagonist, montelukast, can reduce the need for inhaled steroid while maintaining the clinical stability of asthmatic patients. Clin Exp Allergy 32: 1180–1186.
61. Tonelli M. Zingoni M. Bacci E. Dente F.L. Di Franco A. Giannini D. et al (2003) Short-term effect of the addition of leukotriene receptor antagonists to the current therapy in severe asthmatics. Pulm Pharmacol Ther 16: 237–240.
62. Vaquerizo M.J. Casan P. Castillo J. Perpiña M. Sanchis J. Sobradillo V. et al (2003) Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax 58: 204–211.
63. Villaran C. O'Neill S.J. Helbling A. van Noord J.A. Lee T.H. Chuchalin A.G. et al (1999) Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. J Allergy Clin Immunol 104: 547–553.
64. Virchow J.C. Metha A. Ljungblad L. Mitfessel H. the MONICA study group (2010) Add-on montelukast in inadequately controlled asthma patients in a 6-month open-label study: The MONtelukast In Chronic Asthma (MONICA) study. Respir Med 104: 644–651.
65. Wenzel S.E. (2006) Asthma: Defining of the persistent adult phenotypes. Lancet 368: 804–813.